ASCO ConferenceASCO conference at the end of May 2009.
I guess the new drug landscape is pretty much set by now.
Tarceva is weak, has new undesirable side effects.
Iressa has revived
Bristol-Squidd/Exelixis is gearing up as a threat to all. However, significant side-effects are now noteworthy…
Other known drugs are failing trials.
Biomarkers are now set up to filter cancer patients, shrinking market for existing cancer drugs.
KRAS is the buzz word.
I guess the logical conclusion would be that TLN-4601 is a strategic investment for all to consider. The competitive landscape pushes for a takeover of TLN. It’s was obvious now it’s even clearer.
The odds for a lucrative Takeover just got better. Nice Friday.
Market is going stir attention toward the oncology sub-segment as a new defensive-growth area.